Lantheus Holdings, Inc. (LNTH): Cash & Equivalents
$359.12M
As of 2025-12-31
$593.30M
As of 2026-06-30
-4.8%
3-year compound annual growth
+35.2%
5-year compound annual growth
+28.8%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $359.12M | -60.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $912.81M | +27.9% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $713.66M | +71.7% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $415.65M | +321.9% | 2025-02-26, Balance as of period end |
| 2021-12-31 | $98.51M | +23.7% | 2024-02-22, Balance as of period end |
| 2020-12-31 | $79.61M | -14.3% | 2023-02-23, Balance as of period end |
| 2019-12-31 | $92.92M | -18.1% | 2022-02-24, Balance as of period end |
| 2018-12-31 | $113.40M | +48.6% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $76.29M | +49.1% | 2019-02-20, Balance as of period end |
| 2016-12-31 | $51.18M | +79.0% | 2019-02-20, Balance as of period end |
| 2015-12-31 | $28.60M | +44.9% | 2018-02-26, Balance as of period end |
| 2014-12-31 | $19.74M | +6.2% | 2017-02-23, Balance as of period end |
| 2013-12-31 | $18.58M | n/a | 2016-03-02, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $359.12M | -60.7% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $169.80M | +72.7% |
| Neogen Corp (NEOG) | 2026-05-31 | $185.50M | +43.8% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $149.60M | +46.1% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $180.07M | -37.5% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $155.46M | -17.8% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $5.91M | +59.4% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.81M | +1.3% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $1.75M | -0.8% |
Compare LNTH, QDEL, NEOG, MYGN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗